Literature DB >> 12477657

Endoscopic management of vesicoureteral reflux: does it stand the test of time?

Boris Chertin1, Prem Puri.   

Abstract

Endoscopic subureteral injection of tissue-augmenting substances, a 15-minute outpatient procedure has become an alternative to long-term antibiotic prophylaxis and surgical intervention in the treatment of vesicoureteral reflux (VUR) in children. This paper reviews the long-term results of endoscopic treatment of reflux using various tissue-augmenting substances presently available. In terms of effectiveness and long-term successful results, polytetrafluoroethylene is still the most reliable injectable material for the endoscopic treatment of VUR.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12477657     DOI： 10.1016/s0302-2838(02)00447-5

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  19 in total

1.  Endoscopic subureteral injection treatment with calcium hydroxylapatite in primary vesicoureteral reflux.

Authors:  Bilal Eryildirim; Fatih Tarhan; Uğur Kuyumcuoğlu; Erkan Erbay; Gökhan Faydaci
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

2.  Treatment of a leaking ACE conduit with Deflux injections.

Authors:  A Koivusalo; M P Pakarinen; R J Rintala
Journal:  Pediatr Surg Int       Date:  2006-12       Impact factor: 1.827

3.  The treatment of vesicoureteral reflux in children by endoscopic sub-mucosal intra-ureteral injection of dextranomer/hyaluronic acid: A case-series, multi-centre study.

Authors:  Osama Bawazir
Journal:  Electron Physician       Date:  2017-04-25

4.  Endoscopic correction of complex cases of vesicoureteral reflux utilizing Vantris as a new non-biodegradable tissue-augmenting substance.

Authors:  Boris Chertin; Wael Abu Arafeh; Stanislav Kocherov
Journal:  Pediatr Surg Int       Date:  2014-04       Impact factor: 1.827

5.  Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model.

Authors:  Abdol-Mohammad Kajbafzadeh; Shabnam Sabetkish; Reza Khorramirouz; Nastaran Sabetkish
Journal:  Int Urol Nephrol       Date:  2017-02-16       Impact factor: 2.370

6.  Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux.

Authors:  Mathew D Sorensen; Martin A Koyle; Charles A Cowan; Ismael Zamilpa; Margarett Shnorhavorian; Thomas S Lendvay
Journal:  Pediatr Surg Int       Date:  2010-02-07       Impact factor: 1.827

Review 7.  [Vesicorenal reflux].

Authors:  M Fisch
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

8.  Combination of calcium hydroxyapatite and autologous blood for endoscopic treatment of vesicoureteral reflux in children.

Authors:  Roozbeh Tanhaeivash; Abdol-Mohammad Kajbafzadeh; Atefeh Zeinoddini; Neda Khalili; Mona Vahidi Rad; Reza Heidari
Journal:  Int Urol Nephrol       Date:  2014-02-20       Impact factor: 2.370

9.  The KIDSTEM European Research Training Network: Developing a Stem Cell Based Therapy to Replace Nephrons Lost through Reflux Nephropathy.

Authors:  Patricia Murray; Giovanni Camussi; Jamie A Davies; David Edgar; Markus Hengstschlager; Simon Kenny; Giuseppe Remuzzi; Carsten Werner
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

10.  Has the data efflux regarding the promising outcome following injection of deflux changed the management of adult vesicoureteral reflux?

Authors:  D E Zilberman; Y Mor
Journal:  Adv Urol       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.